scholarly journals Current status of imaging in nonalcoholic fatty liver disease

2018 ◽  
Vol 10 (8) ◽  
pp. 530-542 ◽  
Author(s):  
Qian Li ◽  
Manish Dhyani ◽  
Joseph R Grajo ◽  
Claude Sirlin ◽  
Anthony E Samir
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Current Status ◽  
Nonalcoholic Fatty Liver

scholarly journals Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease

2021 ◽  
Vol 22 (14) ◽  
pp. 7348
Author(s):  
Olivia Wegrzyniak ◽  
Maria Rosestedt ◽  
Olof Eriksson
Keyword(s):  
Liver Disease ◽  
Molecular Imaging ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Imaging Techniques ◽  
Current Status ◽  
Nonalcoholic Fatty Liver ◽  
Positron Emission ◽  
Activated Fibroblasts

Pathological fibrosis of the liver is a landmark feature in chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Diagnosis and assessment of progress or treatment efficacy today requires biopsy of the liver, which is a challenge in, e.g., longitudinal interventional studies. Molecular imaging techniques such as positron emission tomography (PET) have the potential to enable minimally invasive assessment of liver fibrosis. This review will summarize and discuss the current status of the development of innovative imaging markers for processes relevant for fibrogenesis in liver, e.g., certain immune cells, activated fibroblasts, and collagen depositions.

scholarly journals Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis

2019 ◽  
Vol 19 (3) ◽  
pp. 187-198 ◽  
Author(s):  
Jia-Zhen Zhang ◽  
Jing-Jing Cai ◽  
Yao Yu ◽  
Zhi-Gang She ◽  
Hongliang Li
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Current Status ◽  
Imaging Biomarkers ◽  
Nonalcoholic Fatty Liver ◽  
Advantages And Disadvantages ◽  
Diagnostic Approaches

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease and a major cause of related complications such as cirrhosis and hepatocellular carcinoma (HCC). NAFLD progresses through the stages of simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and HCC. However, NAFLD usually cannot be diagnosed in a timely manner, which is largely attributed to the asymptomatic features of NAFLD patients and the lack of an effective and accurate noninvasive screening approach. Although liver biopsy has been recognized as a gold standard for diagnosing NAFLD, this approach is not suitable for screening and monitoring NAFLD because of its high cost and invasiveness. Several noninvasive screening and diagnostic systemic assessments have been developed in recent years for NAFLD evaluation. Here we summarize the current status and methods for NAFLD diagnosis, including both noninvasive (imaging, biomarkers) and invasive (liver biopsy) assessments. We further discuss the advantages and disadvantages of these developed diagnostic approaches for NAFLD.

scholarly journals Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

Cells ◽  
2019 ◽  
Vol 8 (8) ◽  
pp. 845 ◽  
Author(s):  
Hannah Drescher ◽  
Sabine Weiskirchen ◽  
Ralf Weiskirchen
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Nonalcoholic Steatohepatitis ◽  
Fatty Liver Disease ◽  
Sampling Error ◽  
Imaging Techniques ◽  
Current Status ◽  
Nonalcoholic Fatty Liver ◽  
Public Health Burden

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries with almost 25% affected adults worldwide. The growing public health burden is getting evident when considering that NAFLD-related liver transplantations are predicted to almost double within the next 20 years. Typically, hepatic alterations start with simple steatosis, which easily progresses to more advanced stages such as nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. This course of disease finally leads to end-stage liver disease such as hepatocellular carcinoma, which is associated with increased morbidity and mortality. Although clinical trials show promising results, there is actually no pharmacological agent approved to treat NASH. Another important problem associated with NASH is that presently the liver biopsy is still the gold standard in diagnosis and for disease staging and grading. Because of its invasiveness, this technique is not well accepted by patients and the method is prone to sampling error. Therefore, an urgent need exists to find reliable, accurate and noninvasive biomarkers discriminating between different disease stages or to develop innovative imaging techniques to quantify steatosis.

scholarly journals Current Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

2012 ◽  
Vol 26 (6) ◽  
pp. 353-357 ◽  
Author(s):  
Melanie D Beaton
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Lifestyle Modification ◽  
Treatment Options ◽  
Western Society ◽  
Current Status ◽  
Treatment Modalities ◽  
Nonalcoholic Fatty Liver

Nonalcoholic fatty liver disease is the leading cause of liver disease in western society. It is a cause of end-stage liver disease, with increased mortality secondary to cirrhosis and its complications. It is also recognized that cardiovascular disease is a significant cause of death in these patients. Significant work evaluating various treatments has been performed in recent years; however, to date, no ideal therapy exists. Lifestyle modification remains the cornerstone of management. The present article reviews the current status of various treatment modalities evaluated in nonalcoholic fatty liver disease.

Sign in / Sign up

Export Citation Format

Share Document